Core Insights - Ligand Pharmaceuticals announced participation in upcoming investor conferences, with CEO Todd Davis and CFO Tavo Espinoza scheduled for one-on-one meetings with investors [1][4] Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [2] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [2] - Ligand partners with leading pharmaceutical companies to leverage their strengths in late-stage development, regulatory management, and commercialization [2] - The company operates two royalty-generating technology platforms: Captisol®, which enhances drug solubility and stability, and NITRICIL™, which allows for tunable dosing and adjustable drug release profiles [2] - Ligand has established alliances and licenses with major pharmaceutical companies, including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [2]